Indeed, the WGCNA of TCGA-LUAD cohort revealed that patients with this tumor phenotype had down-regulated an extensive gene network led by SASH3 and including IKZF1, IL10RA, CD53 and SNX20, all involved in immune activation. This evidence concerns the gene CD53 and neoplasm.